MetLife Investment Management’s LeMaitre Vascular LMAT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.22M | Buy |
12,745
+1,162
| +10% | +$119K | 0.01% | 1418 |
|
|
2026
Q1 | $1.26M | Sell |
11,583
-96
| -0.8% | -$9.15K | 0.01% | 1290 |
|
|
2025
Q4 | $947K | Sell |
11,679
-558
| -5% | -$48K | ﹤0.01% | 1459 |
|
|
2025
Q3 | $1.07M | Hold |
12,237
| – | – | 0.01% | 1403 |
|
|
2025
Q2 | $1.02M | Hold |
12,237
| – | – | 0.01% | 1305 |
|
|
2025
Q1 | $1.03M | Sell |
12,237
-197
| -2% | -$18.3K | 0.01% | 1349 |
|
|
2024
Q4 | $1.15M | Buy |
12,434
+695
| +6% | +$66.8K | 0.01% | 1340 |
|
|
2024
Q3 | $1.09M | Hold |
11,739
| – | – | 0.01% | 1346 |
|
|
2024
Q2 | $966K | Buy |
11,739
+1,320
| +13% | +$97K | 0.01% | 1364 |
|
|
2024
Q1 | $691K | Hold |
10,419
| – | – | ﹤0.01% | 1505 |
|
|
2023
Q4 | $591K | Hold |
10,419
| – | – | ﹤0.01% | 1590 |
|
|
2023
Q3 | $568K | Hold |
10,419
| – | – | ﹤0.01% | 1550 |
|
|
2023
Q2 | $701K | Buy |
10,419
+541
| +5% | +$33K | 0.01% | 1477 |
|
|
2023
Q1 | $508K | Hold |
9,878
| – | – | ﹤0.01% | 1629 |
|
|
2022
Q4 | $455K | Hold |
9,878
| – | – | ﹤0.01% | 1700 |
|
|
2022
Q3 | $501K | Hold |
9,878
| – | – | ﹤0.01% | 1632 |
|
|
2022
Q2 | $450K | Sell |
9,878
-2,214
| -18% | -$99K | ﹤0.01% | 1735 |
|
|
2022
Q1 | $562K | Buy |
12,092
+4,441
| +58% | +$199K | ﹤0.01% | 1702 |
|
|
2021
Q4 | $384K | Hold |
7,651
| – | – | ﹤0.01% | 1648 |
|
|
2021
Q3 | $406K | Hold |
7,651
| – | – | ﹤0.01% | 1650 |
|
|
2021
Q2 | $467K | Hold |
7,651
| – | – | ﹤0.01% | 1608 |
|
|
2021
Q1 | $373K | Hold |
7,651
| – | – | ﹤0.01% | 1692 |
|
|
2020
Q4 | $310K | Hold |
7,651
| – | – | ﹤0.01% | 1752 |
|
|
2020
Q3 | $249K | Hold |
7,651
| – | – | ﹤0.01% | 1728 |
|
|
2020
Q2 | $202K | Hold |
7,651
| – | – | ﹤0.01% | 1898 |
|
|
2020
Q1 | $191K | Hold |
7,651
| – | – | ﹤0.01% | 1725 |
|
|
2019
Q4 | $275K | Hold |
7,651
| – | – | ﹤0.01% | 1807 |
|
|
2019
Q3 | $262K | Hold |
7,651
| – | – | ﹤0.01% | 1790 |
|
|
2019
Q2 | $214K | Sell |
7,651
-15,302
| -67% | -$425K | ﹤0.01% | 1990 |
|
|
2019
Q1 | $711K | Buy |
22,953
+15,302
| +200% | +$408K | ﹤0.01% | 1867 |
|
|
2018
Q4 | $181K | Hold |
7,651
| – | – | ﹤0.01% | 1967 |
|
|
2018
Q3 | $296K | Hold |
7,651
| – | – | ﹤0.01% | 1864 |
|
|
2018
Q2 | $256K | Hold |
7,651
| – | – | ﹤0.01% | 1797 |
|
|
2018
Q1 | $277K | Hold |
7,651
| – | – | ﹤0.01% | 1723 |
|
|
2017
Q4 | $244K | Buy |
+7,651
| New | +$262K | ﹤0.01% | 1825 |
|
Other funds holding LMAT
CCA
CAM
CCM
MetLife Investment Management's LMAT Position: Q2 2026 in Review
MetLife Investment Management increased its LeMaitre Vascular (LMAT) stake by 10% in Q2 2026, buying an estimated $119K and bringing the position to 12,745 shares worth $1.22M. The position accounts for 0.01% of the portfolio, ranked #1418.
MetLife Investment Management first reported a position in LMAT in Q4 2017 and has held it in 35 quarters since. The position peaked at $1.26M in Q1 2026. 326 funds tracked by Wall St. Rank hold LMAT as of Q2 2026.
- MetLife Investment Management held 12,745 shares of LeMaitre Vascular worth $1.22M as of Q2 2026.
- MetLife Investment Management bought 1,162 LeMaitre Vascular shares in Q2 2026, an estimated $119K.
- LeMaitre Vascular made up 0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1418 holding.
- MetLife Investment Management first reported a position in LeMaitre Vascular in Q4 2017 and has held it in 35 quarters since.
- MetLife Investment Management's LeMaitre Vascular position peaked at $1.26M in Q1 2026.
- 326 funds tracked by Wall St. Rank held LeMaitre Vascular as of Q2 2026.
Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.